 |
|
Clinical Heterogeneity of the LRRK2 G2019S Mutation
Spiridon Papapetropoulos, MD;
Carlos Singer, MD;
Owen A. Ross, PhD;
Mathias Toft, MD;
Joseph L. Johnson, PhD;
Matthew J. Farrer, PhD;
Deborah C. Mash, PhD
Arch Neurol. 2006;63:1242-1246.
Background Several pathogenic mutations have been reported in the leucine-rich repeat kinase 2 gene (LRRK2) that cause parkinsonism. The "common" LRRK2 G2019S kinase domain substitution has been reported to account for approximately 5% of familial and 1% of sporadic Parkinson disease.
Objective To observe the clinical heterogeneity presented by LRRK2 kinase mutation carriers.
Design, Setting, and Participants We screened 130 patients with pathologically confirmed Parkinson disease and 85 controls for 3 LRRK2 kinase domain pathogenic substitutions: I2012T, G2019S, and I2020T.
Main Outcome Measures Detailed clinical phenotypes for individuals who screened positive for LRRK2 mutations.
Results Five LRRK2 G2019S carriers were identified, of whom 4 had Parkinson disease (clinically and pathologically confirmed), and the fifth was a control subject who died at age 68 years after an acute myocardial infarction with no evidence of neurodegenerative abnormalities. There was no evidence of the I2012T or I2020T mutation in these participants.
Conclusions The underlying disease mechanisms of LRRK2 G2019S–associated parkinsonism are similar to those of typical Parkinson disease. The identification of a control subject raises important questions concerning genetic diagnosis and counseling.
Author Affiliations: Department of Neurology, University of Miami School of Medicine, Miami, Fla (Drs Papapetropoulos, Singer, and Mash); and Department of Neuroscience, Mayo Clinic Jacksonville College of Medicine, Jacksonville, Fla (Drs Ross, Toft, Johnson, and Farrer).
RELATED ARTICLE
The Importance of LRRK2 Mutations in Parkinson Disease
Anthony H. V. Schapira
Arch Neurol. 2006;63(9):1225-1228.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations
Chen-Plotkin et al.
Neurology 2008;70:521-527.
ABSTRACT
| FULL TEXT
The Importance of LRRK2 Mutations in Parkinson Disease.
Schapira
Arch Neurol 2006;63:1225-1228.
FULL TEXT
|
